Last reviewed: May 27, 2026

Last updated: May 27, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes, chills can occur with Ozempic and other GLP-1 receptor agonists, though the incidence remains relatively low in clinical trials. Temperature dysregulation—including chills, flushing, and fever—has been reported across GLP-1 medications, affecting fewer than 5% of users in major studies.

Understanding whether temperature-related side effects are likely for you personally matters when choosing a GLP-1 treatment or dose adjustment. Genetic factors, prior medication responses, and individual metabolic characteristics may influence side effect susceptibility, making a precision-wellness approach valuable for informed decision-making.

Mechanism: Why GLP-1 Agonists May Cause Chills

GLP-1 receptors are distributed throughout the central and peripheral nervous systems, including thermoregulatory centers in the hypothalamus. Activation of these receptors can modulate heat production and distribution, potentially triggering chills as the body adjusts to altered metabolic signaling.

Chills associated with GLP-1 therapy are often accompanied by nausea, vomiting, or fever, suggesting a systemic inflammatory or thermoregulatory response rather than isolated temperature sensitivity. This cluster pattern helps distinguish medication-related chills from infection or other causes.

Side Effect Frequency and Risk Factors Across GLP-1 Medications

Clinical trial data shows temperature dysregulation occurs in a small percentage of GLP-1 users. Risk varies by medication, dose, titration speed, and individual patient factors. The table below summarizes incidence patterns and known risk correlates to help contextualize your personal risk profile.

GLP-1 Medication Chills/Fever Incidence (%) Common Risk Factors Onset Timing
Semaglutide (Ozempic/Wegovy) 1-3% Rapid titration, nausea severity, baseline GI sensitivity Days 1-7 post-injection
Tirzepatide (Mounjaro/Zepbound) 2-4% Dual GIP/GLP-1 activation, higher doses, GI side effects Days 1-5 post-injection
Liraglutide (Saxenda/Victoza) <1% Lower potency, slower onset, milder GI effects Weeks 2-4 of therapy
Retatrutide (investigational) 3-5% Triple agonist activity, dose-dependent, phase 2/3 data Days 1-7 post-injection

Who Is Most at Risk: Clinical and Genetic Considerations

Patients experiencing significant nausea or vomiting early in treatment show higher rates of temperature dysregulation. Additionally, those with baseline gastrointestinal sensitivity, rapid dose escalation, or prior adverse reactions to injectable medications report chills more frequently than other users.

Genetic variations in GLP1R signaling pathways and inflammatory response genes may predispose some individuals to heightened GLP-1 side effect sensitivity. While individual genetic testing cannot predict exact medication response, identifying genetic markers in peptide pathways can contextualize your risk profile and inform dose strategy discussions with your provider.

Management Strategies and When to Seek Provider Guidance

Most GLP-1-related chills resolve within 24–48 hours without intervention. Supportive care—increased hydration, rest, and temperature-appropriate clothing—typically suffices. If chills persist beyond 48 hours, are accompanied by high fever (>101.5°F), or occur with severe nausea, contact your healthcare provider to rule out infection or adverse drug reaction.

Dose adjustment, extended titration schedules, or switching medications may be appropriate if chills significantly impact quality of life. Your provider can evaluate whether the benefit-to-risk profile justifies continuation, modification, or discontinuation. Genetic and biomarker insights, when available, can support a more targeted conversation about personalized dose and medication selection.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context about your individual predispositions in GLP-1 pathway signaling. Key variants—including GLP1R rs6923761, GIPR rs1800437, and inflammatory response markers—can reveal whether your genetic profile suggests heightened or typical GLP-1 side effect sensitivity, should be interpreted with a qualified healthcare provider.

The test does not predict exact medication response or guarantee that you will or will not experience chills. Instead, it identifies genetic predispositions that may correlate with GLP-1 tolerance patterns observed in clinical cohorts. This information can support a more informed conversation about starting dose, titration pace, and medication choice.

Combining genetic insights with your medical history, current medications, and baseline GI sensitivity creates a comprehensive picture for personalized GLP-1 planning. Discussing test results with your PlexusDx-partnered provider helps translate genetic data into practical dose and formulation recommendations tailored to your risk profile.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves